Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.51 |
| ▸ | PTGES2 | Q9H7Z7 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CHAT | P28329 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4658400 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2C9NFE2L2MAOBFBP1 | |
| SCHEMBL4057935 | 0.85 | NFE2L2 (0.55) | CYP1A2CYP2C9NFE2L2MAOBFBP1 | |
| SCHEMBL4057931 | 0.85 | NFE2L2 (0.55) | CYP1A2CYP2C9NFE2L2MAOBFBP1 | |
| SCHEMBL4618030 | 0.84 | SMN1; SMN2 (0.49) | CYP1A2CYP2C9NFE2L2MAOBPTGES2 | |
| SCHEMBL11534915 | 0.83 | NFE2L2 (0.54) | CYP1A2CYP2C9NFE2L2MAOBFBP1 | |
| SCHEMBL11534918 | 0.83 | NFE2L2 (0.54) | CYP1A2CYP2C9NFE2L2MAOBFBP1 | |
| SCHEMBL9477610 | 0.81 | LCK (0.62) | MAOBFBP1MAOA | |
| SCHEMBL28850027 | 0.81 | UNG (0.44) | CYP1A2CYP2C9NFE2L2FBP1MEN1 | |
| SCHEMBL5417301 | 0.81 | CYP1A2 (0.46) | CYP1A2CYP2C9NFE2L2MAOBPTGES2 | |
| SCHEMBL5420983 | 0.80 | PTGES2 (0.50) | CYP1A2CYP2C9NFE2L2MAOBPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | claimed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | claimed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| EP-1684744-A4 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-17 | — | — | EP | disclosed |
| EP-1684744-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| WO-2005032472-A2 | PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119266-A1 | Pyrrolidine and piperidine derivatives as factor Xa inhibitors | PEPD, SERPINE1, PRSS1 | CYP1A2 3037/4885CYP2C9 2008/4885NFE2L2 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.